The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Paul, S., Breuninger, L. M., Tew, K. D., Shen, H., & Kruh, G. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.14.6929 · Cited by 89
RetractedSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Estrogen receptors and human disease
Deroo, B. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27987 · Cited by 1,320
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?
Brenton, J. D., Carey, L. A., Ahmed, A. A., & Caldas, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3845 · Cited by 953
Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., Yu, J. S., Malmström, P.-O., Mansukhani, M., Enoksson, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472-can-04-3913 · Cited by 875
Triple-Negative Breast Cancer: An Unmet Medical Need
Hudis, C. A., & Gianni, L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s1-01 · Cited by 780
Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., & Deeley, R. G. (1994) · PubMed · Cited by 770
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Self-citationBachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump.
Zaman, G. J., Flens, M. J., van Leusden, M. R., de Haas, M., Mülder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F., & Broxterman, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8822 · Cited by 680
Extending Survival with Chemotherapy in Metastatic Breast Cancer
O'Shaughnessy, J. (2005) · The Oncologist · doi:10.1634/theoncologist.10-90003-20 · Cited by 668
Mechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer
Vu, T., & Claret, F. X. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00062 · Cited by 606
Triple-negative breast cancer: epidemiological considerations and recommendations
Boyle, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds187 · Cited by 593
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
Juric, D., Castel, P., Griffith, M., Griffith, O. L., Won, H. H., Ellis, H., Ebbesen, S. H., Ainscough, B. J., Ramu, A., Iyer, G., et al. (2015) · Nature · doi:10.1038/nature13948 · Cited by 588
Loe, D. W., Almquist, K. C., Deeley, R. G., & Cole, S. P. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.16.9675 · Cited by 560
Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., & Piwnica-Worms, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3900 · Cited by 531
Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 523
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Mitri, Z., Constantine, T., & O'Regan, R. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 519
Resistance to Trastuzumab in Breast Cancer
Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 505
André, F., O'Regan, R., Ozguroglu, M., Toi, M., Xu, B., Jerusalem, G., Masuda, N., Wilks, S., Arena, F., Isaacs, C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70138-x · Cited by 493
The physiological function of drug-transporting P-glycoproteins
Schinkel, A. H. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0068 · Cited by 458
Robey, R. W., To, K. K. K., Polgar, O., Dohse, M., Fetsch, P., Dean, M., & Bates, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.003 · Cited by 449
LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., & Sliwkowski, M. X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0762 · Cited by 444
Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.
Hooijberg, J. H., Broxterman, H. J., Kool, M., Assaraf, Y. G., Peters, G. J., Noordhuis, P., Scheper, R. J., Borst, P., Pinedo, H. M., & Jansen, G. (1999) · PubMed · Cited by 442
HER2 therapy: Molecular mechanisms of trastuzumab resistance
Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 433
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
Hu, R., Dawood, S., Holmes, M. D., Collins, L. C., Schnitt, S. J., Cole, K., Marotti, J. D., Hankinson, S. E., Colditz, G. A., & Tamimi, R. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2021 · Cited by 396
Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Dai, C.-L., Tiwari, A. K., Wu, C.-P., Su, X.-D., Wang, S.-R., Liu, D.-G., Ashby, C. R., Huang, Y., Robey, R. W., Liang, Y.-J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0499 · Cited by 386
Understanding and treating triple-negative breast cancer
Carey, L., & Anders, C. (2021) · PubMed · doi:10.17615/85ph-f542 · Cited by 351
DeMichele, A., Clark, A. S., Tan, K. S., Heitjan, D. F., Gramlich, K., Gallagher, M., Lal, P., Feldman, M., Zhang, P., Colameco, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2258 · Cited by 343
Pusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
Structure and Function of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)
Ni, Z., Bikadi, Z., F. Rosenberg, M., & Mao, Q. (2010) · Current Drug Metabolism · doi:10.2174/138920010792927325 · Cited by 277
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
Tamoxifen (‘Nolvadex’): a review
Clemons, M., Danson, S., & Howell, A. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)00036-1 · Cited by 229
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer
van de Ven, S., Smit, V. T. H. B. M., Dekker, T. J. A., Nortier, J. W. R., & Kroep, J. R. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.11.006 · Cited by 217
Breuninger, L. M., Paul, S., Gaughan, K., Miki, T., Chan, A. M.-L., Aaronson, S. A., & Kruh, G. D. (1995) · PubMed · Cited by 209
Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance
Chen, K. G., & Sikic, B. I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1590 · Cited by 197
von Minckwitz, G., Schwedler, K., Schmidt, M., Barinoff, J., Mundhenke, C., Cufer, T., Maartense, E., de Jongh, F. E., Baumann, K. H., Bischoff, J., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.021 · Cited by 181
Gelmon, K. A., Boyle, F. M., Kaufman, B., Huntsman, D. G., Manikhas, A., Di Leo, A., Martin, M., Schwartzberg, L. S., Lemieux, J., Aparicio, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.9590 · Cited by 178
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Nooter, K., Westerman, A. M., Flens, M. J., Zaman, G. J., Scheper, R. J., van Wingerden, K. E., Burger, H., Oostrum, R. G., Boersma, T., & Sonneveld, P. (1995) · PubMed · Cited by 174
Miller, T. W., Pérez-Torres, M., Narasanna, A., Guix, M., Stål, O., Pérez-Tenorio, G., Gonzalez-Angulo, A. M., Hennessy, B. T., Mills, G. B., Kennedy, J. P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0042 · Cited by 168
ABCG2: the key to chemoresistance in cancer stem cells?
An, Y., & Ongkeko, W. M. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903228834 · Cited by 162
Multidrug Resistance/P-Glycoprotein and Breast Cancer: Review and Meta-Analysis
Clarke, R., Leonessa, F., & Trock, B. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.009 · Cited by 159
Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies
Wind, N. S., & Holen, I. (2011) · International Journal of Breast Cancer · doi:10.4061/2011/967419 · Cited by 158
Nooter, K., de la Rivière, G. B., Look, M. P., van Wingerden, K. E., Henzen-Logmans, S. C., Scheper, R. J., Flens, M. J., Klijn, J. G. M., Stoter, G., & Foekens, J. A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.414 · Cited by 153
Pályi‐Krekk, Z., Barok, M., Isola, J. J., Tammi, M., ̋si, J. S., & Nagy, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.018 · Cited by 149
Harbeck, N., Huang, C., Hurvitz, S. A., Yeh, D., Shao, Z., Im, S., Jung, K. H., Shen, K., Ro, J., Jassem, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00540-9 · Cited by 149
Triple-negative breast cancer: new perspectives for targeted therapies
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Minozzi, M., Frati, L., Papa, A., & Vici (2015) · OncoTargets and Therapy · doi:10.2147/ott.s67673 · Cited by 140
Multidrug-resistant breast cancer: current perspectives
Tomlinson, D. C., Martin, H. L., & Smith, L. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s37638 · Cited by 140
The ABCG family of membrane‐associated transporters: you don't have to be big to be mighty
Kerr, I. D., Haider, A. J., & Gelissen, I. C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01177.x · Cited by 132
Beaver, J. A., & Park, B. H. (2012) · Future Oncology · doi:10.2217/fon.12.49 · Cited by 130
Investigational ABC transporter inhibitors
Falasca, M., & Linton, K. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.679339 · Cited by 128
Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy.
Lockhart, A. C., Tirona, R. G., & Kim, R. B. (2003) · PubMed · Cited by 122
Chemotherapy-Resistant Metastatic Breast Cancer
Marquette, C., & Nabell, L. M. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0184-6 · Cited by 103
Perez, E. A. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0005-6 · Cited by 101
Takenaka, K., Morgan, J. A., Scheffer, G. L., Adachi, M., Stewart, C. F., Sun, D., Leggas, M. L., Ejendal, K. F. K., Hrycyna, C. A., & Schuetz, J. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4720 · Cited by 100
Zhang, D., Pal, A., Bornmann, W. G., Yamasaki, F., Esteva, F. J., Hortobágyi, G. N., Bartholomeusz, C., & Ueno, N. T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0168 · Cited by 97
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Kawabata, S., Oka, M., Soda, H., Shiozawa, K., Nakatomi, K., Tsurutani, J., Nakamura, Y., Doi, S., Kitazaki, T., Sugahara, K., et al. (2003) · PubMed · Cited by 95
Expression Pattern of MRP in Human Tissues and Adult Solid Tumor Cell Lines
Kruh, G. D., Gaughan, K., Godwin, A. K., & Chan, A. M.-L. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.16.1256 · Cited by 93
Triple-negative breast cancer: are we making headway at least?
Arnedos, M., Bihan, C., Delaloge, S., & André, F. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012444711 · Cited by 90
Chang, X.-B. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9041-7 · Cited by 87
Tang, Y., Lei, T., Manchanda, R., Nagesetti, A., Fernandez-Fernandez, A., Srinivasan, S., & McGoron, A. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0231-6 · Cited by 86
Self-citationTamoxifen resistance: From cell culture experiments towards novel biomarkers
Naß, N., & Kalinski, T. (2015) · Pathology - Research and Practice · doi:10.1016/j.prp.2015.01.004 · Cited by 82
Geyer, F. C., & Reis-Filho, J. S. (2008) · International Journal of Surgical Pathology · doi:10.1177/1066896908328577 · Cited by 80
Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics
Jani, M., Temesszentandrási‐Ambrus, C., Magnan, R., Jakab, K. T., Beéry, E., Zolnerciks, J. K., & Krajcsi, P. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1224-8 · Cited by 78
Krop, I. E., Johnston, S. R. D., Mayer, I. A., Dickler, M. N., Ganju, V., Forero, A., Melichar, B., Morales, S. M., BOER, R. D., Gendreau, S. B., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s2-02 · Cited by 60
Expression profiling technology: its contribution to our understanding of breast cancer
Rakha, E. A., El‐Sayed, M. E., Reis-Filho, J. S., & Ellis, I. O. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02894.x · Cited by 57
Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells
Selever, J., Gu, G., Lewis, M. T., Beyer, A. R., Herynk, M. H., Covington, K. R., Tsimelzon, A. I., Dontu, G., Provost, P., Pietro, A. D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1403 · Cited by 55
Giessrigl, B., Schmidt, W. M., Kalipciyan, M., Jeitler, M., Bilban, M., Gollinger, M., Krieger, S., Jäger, W. R., Mader, R. M., & Krupitza, G. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.583 · Cited by 51
Mross, K. B., Bohn, C., Edler, L., Jonat, W., Queißer, W., Heidemann, E., Goebel, M., & HOSSFELD, D. K. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058356 · Cited by 51
Huh, H. J., Park, C., Jang, S., Seo, E., Chi, H., Lee, J., Lee, K., Seo, J. J., Moon, H. N., & Ghim, T. T. (2006) · Journal of Korean Medical Science · doi:10.3346/jkms.2006.21.2.253 · Cited by 50
Reversing multidrug resistance by tyrosine kinase inhibitors
He, M., & Wei, M. (2012) · 癌症:英文版 · doi:10.5732/cjc.011.10315 · Cited by 49
Warner, E., Hedley, D. W., Andrulis, I. L., Myers, R. E., Trudeau, M. G., Warr, D. G., Pritchard, K. I., Blackstein, M. E., Goss, P. E., Franssen, E., et al. (1998) · PubMed · Cited by 48
The Promise of Antibody–Drug Conjugates
Teicher, B. A., & Doroshow, J. H. (2012) · New England Journal of Medicine · doi:10.1056/nejme1211736 · Cited by 48
Chevillard, S., Lebeau, J., Pouillart, P., de Toma, C., Beldjord, C., Asselain, B. J. R., Klijanienko, J., Fourquet, A., Magdelénat, H., & Vielh, P. R. (1997) · PubMed · Cited by 46
Hutson, J. R., Koren, G., & Matthews, S. G. (2010) · Placenta · doi:10.1016/j.placenta.2010.02.010 · Cited by 45
The phenomenon of multi-drug resistance in the treatment of malignant tumors.
Vtorushin, S. V., Khristenko, К. Y., Zavyalova, M. V., Михайлович, П. В., Литвяков, Н. В., Denisov, E. V., Dulesova, A. Y., & Чердынцева, Н. В. (2014) · PubMed · Cited by 42
Endocrine resistance in breast cancer: From cellular signaling pathways to epigenetic mechanisms
Bianco, S., & Gévry, N. Y. (2012) · Transcription · doi:10.4161/trns.20496 · Cited by 41
Towards a targeted multi-drug delivery approach to improve therapeutic efficacy in breast cancer
Wang, B., Rosano, J. M., Cheheltani, R., Achary, M. P., & Kiani, M. F. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.513968 · Cited by 39
Self-citationEpigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance
Raha, P., Thomas, S., & Münster, P. N. (2011) · Epigenomics · doi:10.2217/epi.11.72 · Cited by 38
Radiation-Guided Targeting of Combretastatin Encapsulated Immunoliposomes to Mammary Tumors
Pattillo, C. B., Venegas, B., Donelson, F. J., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9826-1 · Cited by 37
Synthesis and Quantitative Structure–Activity Relationships of Selective BCRP Inhibitors
Marighetti, F., Steggemann, K., Hanl, M., & Wiese, M. (2012) · ChemMedChem · doi:10.1002/cmdc.201200377 · Cited by 33
Mayer, I. A. (2013) · PubMed · Cited by 30
Thomas, S., Thurn, K. T., Raha, P., Chen, S., & Münster, P. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068973 · Cited by 30
Gago, F. E., Tello, O. M., Diblasi, Á. M., et al. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00140-x · Cited by 29
Sajadieh, S. S., Mohammadizadeh, F., Sajjadieh, H., & Kasaei, Z. (2014) · Advanced Biomedical Research · doi:10.4103/2277-9175.133260 · Cited by 8
Zelnak, A. B., & Wisinski, K. B. (2014) · Cancer · doi:10.1002/cncr.28815 · Cited by 8
Cited by
Chen, Q., Li, Q., Liang, Y., Zu, M., Chen, N., Canup, B. S. B., Luo, L., Wang, C., Zeng, L., & Xiao, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.08.016 · Cited by 361
Emerging roles of aerobic glycolysis in breast cancer
Wu, Z., Wu, J., Zhao, Q., Fu, S., & Jin, J. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02187-8 · Cited by 255
Tang, Y., Soroush, F., Sheffield, J. B., Wang, B., Prabhakarpandian, B., & Kiani, M. F. (2017) · Scientific Reports · doi:10.1038/s41598-017-09815-9 · Cited by 102
Self-citation
Metadata
- Authors
- Tang, Y., Wang, Y., Kiani, M. F., & Wang, B.
- Venue
- Clinical Breast Cancer
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 16
- Issue
- 5
- Pages
- 335-343
- ISSN
- 1526-8209 (ISSN-L)
- OpenAlex
- W2359219670
- Cited by
- 265
- References
- 113
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.